Copyright
©The Author(s) 2025.
World J Hepatol. Jan 27, 2025; 17(1): 100392
Published online Jan 27, 2025. doi: 10.4254/wjh.v17.i1.100392
Published online Jan 27, 2025. doi: 10.4254/wjh.v17.i1.100392
Parameters | Pre-hormone therapy | 2-3 months after hormone therapy | Z/t | P value |
IgG | 24.83 ± 4.32 | 16.09 ± 2.87 | 16.263 | < 0.001 |
ALT | 41 (33.85-255.5) | 34.7 (28.5-39.5) | 1.153 | 0.249 |
AST | 51 (39-221) | 33 (27.5-43) | 2.274 | 0.023 |
TBIL | 24.3 (14.9-45.5) | 18.5 (13.15-46.25) | 0.454 | 0.65 |
ALP | 115.58 ± 35.99 | 82.72 ± 28.13 | 4.035 | 0.002 |
GGT | 100.26 ± 72.99 | 63.22 ± 24.96 | 1.591 | 0.138 |
TBA | 39.7 (18.5-74.55) | 49.2 (12.95-90.15) | 0.874 | 0.382 |
ALB | 32.31 ± 6.36 | 36.18 ± 4.57 | 2.983 | 0.011 |
- Citation: Jiang ML, Xu F, Li JL, Luo JY, Hu JL, Zeng XQ. Clinical features of abnormal α-fetoprotein in 15 patients with chronic viral hepatitis B after treatment with antiviral drugs. World J Hepatol 2025; 17(1): 100392
- URL: https://www.wjgnet.com/1948-5182/full/v17/i1/100392.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i1.100392